Patient samples
| Patient . | Age (y) . | Sex . | Source of patient's primary T-ALL . | WBC (×109/L) . | Blasts (%) . | Phenotype of patient's primary T-ALL . |
|---|---|---|---|---|---|---|
| 10155 | 4 | F | Peripheral blood | > 700 | 100 | CD2++CD3− CD4++ CD5++CD7++ CD8++ |
| 26710 | 4 | M | Peripheral blood | 797 | 93 | CD2++ CD3−CD4+ CD5++ CD7++CD8+ |
| 27531 | 6 | M | Peripheral blood | 248 | 88 | CD2++ CD3++CD4+ CD5++ CD7++CD8++ |
| 30749 | 2 | M | Peripheral blood | 393 | 94 | CD2++ CD3++CD4+ CD5++ CD7++CD8++ |
| 08916 | 1 | M | Bone marrow | 416 | 87 | CD2++ CD3+CD4− CD5++ CD7++CD8+ |
| 08948 | 15 | M | Peripheral blood | 143 | 73 | CD2++ CD3++CD5++ CD7++ CD8++ |
| 33205 | 13 | F | Peripheral blood | 327 | 94 | CD2+ CD3++CD4++ CD5++ CD7++CD8++ |
| 32564 | 5 | F | Peripheral blood | 350 | 88 | CD2++ CD3+CD4+ CD5++ CD7++CD8+ |
| Patient . | Age (y) . | Sex . | Source of patient's primary T-ALL . | WBC (×109/L) . | Blasts (%) . | Phenotype of patient's primary T-ALL . |
|---|---|---|---|---|---|---|
| 10155 | 4 | F | Peripheral blood | > 700 | 100 | CD2++CD3− CD4++ CD5++CD7++ CD8++ |
| 26710 | 4 | M | Peripheral blood | 797 | 93 | CD2++ CD3−CD4+ CD5++ CD7++CD8+ |
| 27531 | 6 | M | Peripheral blood | 248 | 88 | CD2++ CD3++CD4+ CD5++ CD7++CD8++ |
| 30749 | 2 | M | Peripheral blood | 393 | 94 | CD2++ CD3++CD4+ CD5++ CD7++CD8++ |
| 08916 | 1 | M | Bone marrow | 416 | 87 | CD2++ CD3+CD4− CD5++ CD7++CD8+ |
| 08948 | 15 | M | Peripheral blood | 143 | 73 | CD2++ CD3++CD5++ CD7++ CD8++ |
| 33205 | 13 | F | Peripheral blood | 327 | 94 | CD2+ CD3++CD4++ CD5++ CD7++CD8++ |
| 32564 | 5 | F | Peripheral blood | 350 | 88 | CD2++ CD3+CD4+ CD5++ CD7++CD8+ |
T-ALL indicates T-cell acute lymphoblastic leukemia; WBC, white blood cell; −, < 10%; +, 10%-90%;++, > 90% as determined by flow cytometry.